However, the role of Her-2 as a poor prognostic factor in breast carcinoma was altered by the introduction of trastuzumab, a monoclonal antibody which targets the Her-2 receptor (Wecsler et al., 2015). This evidence concerns the gene ERBB2 and breast carcinoma.